Financial Report: Merck

Merck

4Q Revenues: $10.5 billion (-7%)

4Q Earnings: $7.3 billion (earnings were $781 million 4Q13)

FY Revenues: $42.2 billion (-4%)

FY Earnings: $11.9 billion (earnings were $4.4 billion FY13)

Comments: Pharmaceutical sales were down 4% to $9.4 billion in the quarter. Zetia/Vytorin, Remicade, and Gardasil sales were all down 10% to $1.0 billion, $557 million, and $356 million, respectively. Januvia sales were up 2% to $1.7 billion. Isentress sales were down 5% to $418 million. Nasonex sales were $268 million, down 18%. Singulair sales were up 7% to $319 million. Animal health sales were 885 million, up 2%. Results in the quarter include a 3% negative impact from foreign exchange and a 7% negative impact from patent expiries and divestitures, including the Consumer Care business.